Bryan Gall, Phd, Mls(Ascp)Cm Email & Phone Number

Colorado Springs, Colorado, United States

United States

• Supervise a team of highly motivated and skilled PhD- and masters-level variant scientists.• Training lead for new team hires, including 20 current members of the variant curation team.• Identify and troubleshoot panel and curation issues as a member of the product support team.• Project manager for self-initiated research projects regarding Horizon carrier screening panel.• Directly support the assistant director as requested.• Critically analyze and interpret clinical genetic information on a comprehensive 274-gene carrier screening panel.• Certified as subject matter expert for Horizon carrier screening panel.

Remote

• Critically analyze and interpret clinical genetic information on a comprehensive 274-gene carrier screening panel• Liaise between the curation team and genetic counselors, clinical lab scientists, and lab directors.• Liaise with the lab directors developing products prior to commercial launch.• Manage technical onboarding and training of new hires.• Work with a team of scientists to develop and curate genetic content for a broad range of genetic disorders• Certified as subject matter expert for Horizon carrier screening panel.

Remote

• Critically analyze and interpret clinical genetic information on a comprehensive 274-gene carrier screening panel.

Memphis, Tennessee

• Works to design, validate, implement, compose standard operating procedures, and troubleshoot clinical sequencing and array assays to consistently improve clinical offerings. - Validations responsible for >$1 million in billable tests.• Acting clinical variant scientist - interpret the clinical consequences of variants (SNV, INDEL, and CNV) identified in patients and aids in the selection and annotation of variants to include in targeted pharmacogenomic and hereditary cancer NGS panels. - Oversaw selection, implementation of variant calling and interpretation bioinformatic pipeline. - Project manager for >$100,000 hereditary cancer panel adoption project. - Subject matter expert in sequencing, variant interpretation for >3,000 samples per year.• Trains medical laboratory scientists on appropriate adoption of newly developed genomic assays.• Acts as a project manager on select genomics ventures within the areas of next-generation sequencing and bioinformatics. - Developed implementation plan and validation plan for CQuentia's cancer panel. - Coordinated multiple third-party bioinformatics teams across the country. - Established CNV capabilities in CQuentia's cancer panel.• Educates and collaborates with the business development teams to develop and implement new genomic projects as seamlessly as possible.

Salt Lake City, Utah

• Reclassify clinically relevant genetic variants to determine pathogenicity• Evaluate new and emerging genetic technology for insurers• Generate literature and visual media to raise awareness of genetic concerns in the clinic.

Portland, Oregon Area

Research focus: using gene-editing and molecular biology (qPCR / RNA-seq) to determine the mechanism of action for small molecule agonists of type I interferon (Gall, J. Virol., 2018; Gall, Methods Mol Biol., 2017; Botto, ... , Gall, MBio, 2019; Pryke, ... , Gall, mBio, 2017; Gall, JEM, in review) • Using genome-editing and deep-sequencing to characterize the molecular signaling pathways activated by individual Interferon Regulatory Factor (IRF) transcription factors. • Employing molecular genetics/genomics to identify of how genetic haplotypes of STING affect responses to these therapeutic small molecules. • Characterization of these drugs for disease-specific therapeutic benefits using molecular biology techniques in cell lines and primary cells, gene editing technology, and in vivo modeling. This work has resulted in two published manuscripts and two manuscripts in preparation.

Morgantown, Wv

Research focus: G protein signaling modulator 3 (GPSM3) genetic variants involvement in leukocyte migration and how mutations in the GPSM3 gene locus may confer a protective phenotype in rheumatoid arthritis (Gall, Genes and Immunity, 2016a; Gall, Genes and Immunity, 2016b). • Created a genetic workflow within the Siderovski laboratory de novo, which developed into the Laboratory of Neuroscience and Genetics of Substance Abuse. • Characterized variants of uncertain significance from clinical samples and in vitro assays, resulting in two publications and used to update the ClinVar database. • Collaborated on exome-seq case study and identified a likely pathogenic compound heterozygous mutation in the HCN1 gene (Yu, Gall, J. Circ., in review).

Toledo St. Vincent Integrated Laboratories (Ohio)

Responsible for the preparation of patient samples for microbiological analysis and data acquisition to aid Medical Doctors in diagnosis and treatment of disease states.

Doctor Of Philosophy (Phd), Cellular And Integrated Physiology, Gpa: 4.0

B.S., Medical Laboratory Sciences, Gpa: 3.96

Activities and Societies: Alpha Chi honors society, Residence Life (Senior Resident Assistant 2010-2011 and Resident Assistant 2009-2010).